Chester County News and Community Website
MALVERN, PA — Amid alarming data from the Centers for Disease Control and Prevention (CDC) illustrating an acceleration of the substance misuse epidemic and drug overdose deaths as a result …
Read More
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer …
Read More
HARRISBURG, PA — The Pennsylvania Department of Human Services (DHS) recently released the latest issue of the Positive Approaches Journal, which aims to provide the most recent research and resources for …
Read More
HARRISBURG, PA — On Monday, Department of Drug and Alcohol Programs (DDAP) Secretary Jen Smith was joined virtually by the Pennsylvania Lottery, the Pennsylvania Gaming Control Board, and the Council …
Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has provided an update on its meeting with …
Read More
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced its CEO, Maria Maccecchini, …
Read More
BERWYN, PA — Melmark announced the receipt of a $21.5 million endowment gift from the Anne and Brutus Kenan fund to further secure the not-for-profit organization’s mission well into the future. Melmark …
Read More BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced it successfully completed the …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration permitted marketing of a new device intended for the temporary reduction of sleep disturbance related to nightmares in adults 22 years …
Read More